All Tox In Focus volumes
Tox In Focus
|
Focused Clinical Reference
Vol. 15  ·  Methamphetamine  ·  July 2026
METHAMPHETAMINE
Isomer testing and the medications that can explain a positive

Methamphetamine is a potent CNS stimulant metabolized to amphetamine. Most urinary positives reflect illicit use, but some result from legitimate medications, and routine LC-MS/MS does not distinguish the d- (illicit or prescription stimulant) from the l- (some decongestants, selegiline) isomer without dedicated isomer testing.1

Why This Matters Now

Stimulant-involved overdose deaths, often methamphetamine combined with fentanyl or heroin, have risen sharply over the past decade.2 Because a positive methamphetamine result can trigger serious consequences such as discontinuation of prescribed controlled substances, accurate interpretation, including isomer analysis when the source is in question, is critical.1

⚠ Before acting on a methamphetamine positive, consider l-isomer sources (some generic decongestant inhalers, selegiline) and request d/l isomer testing; federal programs use a 20% d-isomer threshold to separate illicit from medicinal sources.
Clinical Presentation
INTOXICATION
Euphoria, increased energy, alertness
Agitation, paranoia, psychosis
Tachycardia, hypertension
Hyperthermia
Insomnia, anorexia
WITHDRAWAL
Fatigue, hypersomnia
Depressed mood
Increased appetite
Anxiety, irritability
Craving
Important: A positive methamphetamine result can carry major clinical and legal consequences. When a medicinal source is plausible, use d/l isomer testing (below 20% d-isomer suggests an l-methamphetamine product or selegiline) before concluding illicit use.
UDT Considerations

Amphetamine-class immunoassays are prone to cross-reactivity and false positives; LC-MS/MS specifically identifies methamphetamine and amphetamine. Because standard LC-MS/MS does not separate isomers, d/l isomer analysis helps distinguish illicit d-methamphetamine from l-methamphetamine sources such as selegiline or some decongestants.1 The l-form converts to amphetamine slowly, so an l-methamphetamine positive may show little or no amphetamine.3

Clinical Guidance
  • Confirm amphetamine-class screen positives with LC-MS/MS; screens cross-react with many medications.4
  • When the source is disputed, order d/l isomer testing; a d-isomer fraction below 20% points to an l-methamphetamine product or selegiline.1
  • Review the medication list for benzphetamine, selegiline, and l-methamphetamine decongestants before concluding illicit use.
  • Interpret a methamphetamine positive with little amphetamine cautiously; it can reflect the slowly converting l-isomer.3
  • Screen for concurrent opioid use given rising stimulant-opioid co-use.
Point-of-Care Testing Availability
Available strips
Amphetamine-class immunoassays flag stimulants but are prone to false positives.
Clinical use
Many medications and OTC decongestants cross-react on amphetamine screens.
Limitations
LC-MS/MS confirms methamphetamine and amphetamine; d/l isomer testing can identify the source.
METHAMPHETAMINE  |  Clinical & Program Guidance
Tox In Focus Vol. 15  ·  July 2026  ·  Page 2 of 2
Interpreting the Test Result
▲  If Testing Is Positive

Confirms stimulant exposure. LC-MS/MS detection of methamphetamine and/or amphetamine indicates use within the window of detection.

Source may need isomer testing. Routine testing does not separate illicit d- from medicinal l-methamphetamine; isomer analysis and the table below can.1

Amphetamine may be low or absent. With l-methamphetamine, slow conversion can yield little amphetamine.3

Source and Isomer Interpretation
SourceDetected asIsomerContext
Illicit methamphetamined-MAMP, d-AMPd (≥20%)Illicit use
Desoxyn (d-methamphetamine)d-MAMP, d-AMPd (≥20%)Rx ADHD or weight loss (rare)
Didrex (benzphetamine)d-MAMP, d-AMPd (≥20%)Schedule III weight loss
Selegiline (Emsam, Zelapar)l-MAMP, l-AMPl (<20% d)Parkinson disease, depression
OTC l-methamphetamine inhalerl-AMP (slow)l (<20% d)Nasal decongestant

Federal programs use a 20% d-isomer threshold: at or above 20% d indicates illicit or prescription d-methamphetamine; below 20% d indicates an l-methamphetamine product or selegiline.

Key References
  1. Medical Review Officer Manual for Federal Agency Workplace Drug Testing Programs. Effective February 1, 2024.
  2. Garnett MF, Minino AM. Drug overdose deaths in the United States, 2003-2023. NCHS Data Brief no. 522. National Center for Health Statistics; 2024.
  3. Cody JT, Schwarzhoff R. Interpretation of methamphetamine and amphetamine enantiomer data. J Anal Toxicol. 1993;17:321-326.
  4. Reisfield GM, Goldberger BA, Bertholf RL. 'False-positive' and 'false-negative' test results in clinical urine drug testing. Bioanalysis. 2009;1(5):937-952.
DISCLAIMER: This document is intended for clinical reference and educational purposes only. It does not constitute medical, legal, or professional advice and should not replace independent clinical or programmatic judgment. Content reflects published data available at time of preparation. ToxiPharm LLC makes no warranties regarding completeness or applicability in all settings.  |   © 2026 ToxiPharm LLC  |  toxipharm.org
Back to Tox In Focus ToxiPharm home →